Por: WPLG Local 10 Tech July 12, 2023
BRUSSELS – The European Union on Wednesday slapped a $475 million fine on U.S. biotech giant Illumina for buying cancer-screening company Grail without regulators' approval, the latest setback for the deal.Illumina announced an $7.1 billion acquisition of Grail in 2020, but the European Commission, the EU's executive arm and top antitrust enforcer, said the company broke EU merger rules by completing the deal without its consent. The... + full article
ABC News USA Business July 12, 2023
BRUSSELS -- The European Union on Wednesday slapped a $475 million fine on U.S. biotech giant Illumina for buying out cancer-screening company Grail without the approval of the 27-nation bloc's antitrust watchdog, the latest setback for the deal.Illumina announced an $7.1... + más
Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal | CNBC
FTC orders Illumina to unwind $7B deal for cancer test developer Grail | Fox Business
ABC News USA Health July 12, 2023
ABC News USA Tech July 12, 2023
The New York Times USA Business April 03, 2023
The Federal Trade Commission on Monday ordered Illumina, the leading maker of gene-sequencing machines, to divest Grail, a cancer-test developer.The move by the F.T.C. is the latest development in a case seen by antitrust experts as a to stop big companies from buying fledgling... + más
Fox Business USA Business April 03, 2023
Check out whats clicking on FoxBusiness.com The on Monday ordered life sciences company Illumina to unwind its $7.1 billion acquisition of cancer detection test developer Grail Inc., citing antitrust concerns. The commission voted unanimously in a 4-0 decision to force Illumina... + más
F.T.C. Orders Gene-Sequencing Company Illumina to Divest Acquisition | The New York Times
CNBC USA Health March 24, 2023
In this articleCarl Icahn speaking at Delivering Alpha in New York on Sept. 13, 2016.David A. Grogan CNBCCarl Icahn on Friday alleged that 's directors demanded extra personal liability insurance before the biotech company signed off on a $7.1 billion acquisition of cancer... + más
Icahn proposes three candidates for Illumina’s board — Here’s what could be next in the battle | CNBC
CNBC USA Health March 21, 2023
In this articleCarl IcahnAdam Jeffery CNBC Biotech company pushed back Monday against Carl Icahn's proxy fight over the company's acquisition of cancer test developer Grail, saying the activist investor's board nominees do not add value. The San Diego-based DNA... + más
Carl Icahn claims Illumina directors got extra insurance to close 'disastrous' $7.1 billion Grail deal | CNBC
About iurex | Privacy Policy | Disclaimer |